{"analyses":[{"groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.0001","statisticalMethod":"Kruskal-Wallis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.1","upperLimit":"12.9","value":"12.0"},{"groupId":"OG001","lowerLimit":"12.7","upperLimit":"14.2","value":"13.4"},{"groupId":"OG002","lowerLimit":"9.5","upperLimit":"10.4","value":"9.9"}]}]}],"denomUnitsSelected":"p-PTH measurements","denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"15"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"240"},{"groupId":"OG002","value":"225"}],"units":"p-PTH measurements"}],"description":"Blood samples were acquired once every 4 weeks for safety-purposes.","dispersionType":"95% Confidence Interval","groups":[{"description":"15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.","id":"OG000","title":"Combined Treatment."},{"description":"16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.","id":"OG001","title":"Denosumab Monotherapy"},{"description":"15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.","id":"OG002","title":"Placebo"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Monthly up to one year.","title":"Mean p-PTH During Treatment.","type":"SECONDARY","typeUnitsAnalyzed":"p-PTH measurements","unitOfMeasure":"pmol/l"}